Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Fleming, Jessica A.; Baral, Ranju; Higgins, Deborah; Khan, Sadaf; Kochar, Sonali; Li, You; Ortiz, Justin R.; Cherian, Thomas; Feikin, Daniel R.; Jit, Mark; Karron, Ruth A.; Limaye, Rupali J.; Marshall, Caroline; Munywoki, Patrick K.; Nair, Harish; Newhouse, Lauren; Nyawanda, Bryan; Pecenka, Clint; Regan, Katie; Srikantiah, Padmini; Wittenauer, Rachel; Zar, Heather J.; Sparrow, Erin

doi:10.1016/j.vaccine.2022.09.081

Cited by 7 publications

(3 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While palivizumab is indicated to prevent RSV in high-risk infants and young children, it requires multiple doses and is costly. Hence, the recently approved maternal vaccine and long-acting mAbs can offer more convenient options for RSV prophylaxis and are not limited to high-risk populations; furthermore, both of these new preventive options are projected to be cost-effective [30]. Of importance, cooperation between prenatal and pediatric HCPs, as well as relevant governmental and non-governmental agencies, will be needed to facilitate broad access to these preventives in order to realize the potential public health benefits of RSV immunization [30].…”

Section: Discussionmentioning

confidence: 99%

“…Hence, the recently approved maternal vaccine and long-acting mAbs can offer more convenient options for RSV prophylaxis and are not limited to high-risk populations; furthermore, both of these new preventive options are projected to be cost-effective [30]. Of importance, cooperation between prenatal and pediatric HCPs, as well as relevant governmental and non-governmental agencies, will be needed to facilitate broad access to these preventives in order to realize the potential public health benefits of RSV immunization [30]. Understanding the preferences and priorities of key stakeholders, such as pregnant people and HCPs, may help inform efforts to spur greater immunization coverage, which can, in turn, reduce the substantial mortality and morbidity burden associated with severe illness from RSV among infants.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus

Beusterien,

Law,

Maculaitis

et al. 2024

Vaccines

View full text Add to dashboard Cite

We assessed the impact of respiratory syncytial virus (RSV) preventive characteristics on the intentions of pregnant people and healthcare providers (HCPs) to protect infants with a maternal vaccine or monoclonal antibodies (mAbs). Pregnant people and HCPs who treated pregnant people and/or infants were recruited via convenience sample from a general research panel to complete a cross-sectional, web-based survey, including a discrete choice experiment (DCE) wherein respondents chose between hypothetical RSV preventive profiles varying on five attributes (effectiveness, preventive type [maternal vaccine vs. mAb], injection recipient/timing, type of medical visit required to receive the injection, and duration of protection during RSV season) and a no-preventive option. A best–worst scaling (BWS) exercise was included to explore the impact of additional attributes on preventive preferences. Data were collected between October and November 2022. Attribute-level preference weights and relative importance (RI) were estimated. Overall, 992 pregnant people and 310 HCPs participated. A preventive (vs. none) was chosen 89.2% (pregnant people) and 96.0% (HCPs) of the time (DCE). Effectiveness was most important to preventive choice for pregnant people (RI = 48.0%) and HCPs (RI = 41.7%); all else equal, pregnant people (RI = 5.5%) and HCPs (RI = 7.2%) preferred the maternal vaccine over mAbs, although preventive type had limited influence on choice. Longer protection, protection starting at birth or the beginning of RSV season, and use for both pre-term and full-term babies were ranked highest in importance (BWS). Pregnant people and HCPs strongly preferred a preventive to protect infants against RSV (vs. none), underscoring the need to incorporate RSV preventives into routine care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus

Beusterien,

Law,

Maculaitis

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

“…[ 1 , 2 , 10 , 12 ]. During the attachment, the F protein transitions from a pre-fusion (preF) to post-fusion (postF) conformation, eliciting neutralizing antibodies (NA) that target both preF or postF protein [ 7 , 13 ], as well as the cytotoxic T-lymphocyte response, therefore being a suitable target for vaccine development and preventive immunization strategies with monoclonal antibodies (mAb) [ 13 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)

Riccò,

Cascio,

Corrado

et al. 2024

Vaccines

View full text Add to dashboard Cite

A systematic review with a meta-analysis was performed to gather available evidence on the effectiveness of monoclonal antibody nirsevimab in the prevention of lower respiratory tract diseases (LRTDs) due to respiratory syncytial virus (RSV) in children and newborns (CRD42024540669). Studies reporting on real-world experience and randomized controlled trials (RCTs) were searched for in three databases (PubMed, Embase, and Scopus) until 1 May 2024. Our analysis included five RCTs, seven real-world reports, and one official report from the health authorities. Due to the cross-reporting of RCTs and the inclusion of multiple series in a single study, the meta-analysis was performed on 45,238 infants from 19 series. The meta-analysis documented a pooled immunization efficacy of 88.40% (95% confidence interval (95% CI) from 84.70 to 91.21) on the occurrence of hospital admission due to RSV, with moderate heterogeneity (I2 24.3%, 95% CI 0.0 to 56.6). Immunization efficacy decreased with the overall length of the observation time (Spearman’s r = −0.546, p = 0.016), and the risk of breakthrough infections was substantially greater in studies with observation times ≥150 days compared to studies lasting <150 days (risk ratio 2.170, 95% CI 1.860 to 2.532). However, the effect of observation time in meta-regression analysis was conflicting (β = 0.001, 95% CI −0.001 to 0.002; p = 0.092). In conclusion, the delivery of nirsevimab was quite effective in preventing hospital admissions due to LRTDs. However, further analyses of the whole RSV season are required before tailoring specific public health interventions.

show abstract

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

Fitzpatrick,

Laufer,

Baral

et al. 2023

Vaccine

View full text Add to dashboard Cite

Value profile for respiratory syncytial virus vaccines and monoclonal antibodies

Cited by 7 publications

References 111 publications

Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus

Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus

Impact of Nirsevimab Immunization on Pediatric Hospitalization Rates: A Systematic Review and Meta-Analysis (2024)

Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022

Contact Info

Product

Resources

About